The UK approach to COVID-19 vaccination: why was it so different?

Peter MB English

Abstract

The vaccination campaign in the United Kingdom has been extremely successful. Bold decisions were made to order vaccines early, before we knew if they would be effective, and to vary from the manufacturers’ recommendations by extending the ‘prime-boost’ interval between the first and second doses of the AstraZeneca and Pfizer-BioNTech vaccines. These decisions were controversial at the time but have contributed enormously to the effectiveness of the vaccination programme. This is a personal perspective on the approach to COVID-19 vaccination in the United Kingdom.

Article Details

Article Type

Commentary

DOI

10.7573/dic.2021-4-5

Publication Dates

Accepted: ; Published: .

Citation

English PMB. The UK approach to COVID-19 vaccination: why was it so different? Drugs in Context 2021; 10: 2021-4-5. DOI: 10.7573/dic.2021-4-5

Article Views

Monthly article views (last 12 months)

Drugs in Context PubMed Central
Source HTML views PDF downloads Totals
Drugs in Context since September 15, 2025 28 3 31
PubMed Central since November 1, 2024 635 14 649
Totals 663 17 677
Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.